Patents by Inventor Denis Gravel
Denis Gravel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9636363Abstract: Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2?-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4?, 5?-dichloro-benzoic acid methyl ester hydrochloride.Type: GrantFiled: January 28, 2013Date of Patent: May 2, 2017Assignee: Kiadis Pharma Canada Inc.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20140314720Abstract: Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2?-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl)4?,5?-dichloro-benzoic acid methyl ester hydrochloride.Type: ApplicationFiled: January 28, 2013Publication date: October 23, 2014Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Patent number: 8481489Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: July 9, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8435945Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: May 7, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8383672Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: GrantFiled: June 9, 2011Date of Patent: February 26, 2013Assignee: Kiadis Pharma Canada Inc.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Patent number: 8314066Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 23, 2007Date of Patent: November 20, 2012Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Publication number: 20120004174Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: July 7, 2011Publication date: January 5, 2012Applicant: THERATECHNOLOGIES INC.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20110301573Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: ApplicationFiled: June 9, 2011Publication date: December 8, 2011Inventors: Abdelkri Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20110021616Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: ApplicationFiled: May 24, 2010Publication date: January 27, 2011Applicant: KIADIS PHARMA CANADA INC.Inventors: ABDELKRIM HABI, DENIS GRAVEL, LUC VILLENEUVE, HONGSHENG SU, MARC VAILLANCOURT
-
Publication number: 20100087366Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 8, 2010Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20090253623Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: October 8, 2009Applicant: THERATECHNOLOGIES INC.Inventors: THIERRY ABRIBAT, ANDRE DE VILLERS, ALCIDE CHAPDELAINE, SORAYA ALLAS, DENIS GRAVEL
-
Patent number: 7560574Abstract: Compounds of formula (I) wherein: one of R1, R2, R3, R4 and (R10)n represents halogen and each remaining R1, R2, R3, R4 and R10 group is independently selected from hydrogen, halogen, amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxy, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio, carboxyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, hydroxysulfonyl, amidosulfonyl, dialkylamidosulfonyl, arylalkylamidosulfonyl, formyl, acyl, aroyl, alkyl, alkylene, alkenyl, aryl, aralkyl, vinyl, alkynyl, and corresponding substituted groups; m=0-1; n=1-4, A is nil, O, or NH; R9 is alkylene; -Z is H, amino, dialkylamino, or a trialkylamino salt; X? is an anion; R5, R6, R7 and R8 are independently H or C1-C6 alkyl or R1 in combination with R5 or R6, or R2 in combination with R5 or R6, or R3 in combination wiType: GrantFiled: March 27, 2002Date of Patent: July 14, 2009Assignee: Celmed Biosciences Inc.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20090176869Abstract: Compounds of formula I: in which one of R1, R2, R3, R4 and (R10)n represents halogen and each of the remaining R1, R2, R3, R4 and R10 groups is independently selected from hydrogen, halogen, amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxyl, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio, carboxyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, hydroxysulfonyl, amidosulfonyl, dialkylamidosulfonyl, arylalkylamido-sulfonyl, formyl, acyl, aroyl, alkyl, alkylene, alkenyl, aryl, aralkyl, vinyl, alkynyl and corresponding substituted groups; m=0-1; n=1-4; A is nil, O or NH; R9 is alkylene, Z is H, amino, dialkylamino or trialkylamino salt; X is an anion; and R5, R6, R7 and R8 are independently selected from H and C1-6 alkyl, or R1 with R5 or R6, or R2 with R5 or R6, or R3 with R7 or R8 represents aType: ApplicationFiled: March 13, 2009Publication date: July 9, 2009Applicant: CELMED BIOSCIENCE INC.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Jean-Pierre Forte, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20090088383Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdlaine
-
Publication number: 20090011985Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: October 23, 2007Publication date: January 8, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Patent number: 7365091Abstract: The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula: useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.Type: GrantFiled: May 26, 2006Date of Patent: April 29, 2008Assignee: Enobia PharmaInventors: Denis Gravel, Elaref S. Ratemi, Mostafa Hatam, Guy Boileau, Philippe Crine, Isabelle Lemire
-
Patent number: 7316997Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 20, 2004Date of Patent: January 8, 2008Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20060287280Abstract: The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula: useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.Type: ApplicationFiled: May 26, 2006Publication date: December 21, 2006Applicant: Enobia PharmaInventors: Denis Gravel, Elaref Ratemi, Mostafa Hatam, Guy Boileau, Philippe Crine, Isabelle Lemire
-
Patent number: 7105539Abstract: The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula: useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.Type: GrantFiled: December 3, 2003Date of Patent: September 12, 2006Assignee: Enobia PharmaInventors: Denis Gravel, Elaref S. Ratemi, Mostafa Hatam, Guy Boileau, Philippe Crine, Isabelle Lemire
-
Patent number: 7067488Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1) wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.Type: GrantFiled: September 25, 2003Date of Patent: June 27, 2006Assignee: TheraTechnologies Inc.Inventors: Denis Gravel, Krishna Peri, Thierry Abribat, Abdelkrim Habi